Show simple item record

dc.contributor.editorKwok, Hang Fai
dc.contributor.editorShaw, Christopher
dc.contributor.editorWalker, Brian
dc.date.accessioned2022-01-11T13:52:02Z
dc.date.available2022-01-11T13:52:02Z
dc.date.issued2021
dc.identifierONIX_20220111_9783036525754_928
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/77096
dc.description.abstractIn the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibition strategies are one of the fastest expanding areas in the field of of drugs that show considerable promise. This Special Issue will focus on the recent advances in the discovery and development of protease inhibitors, covering the synthesis of protease inhibitors, the design of new chemical entities acting as inhibitors of special/particular types of proteases, and their mode of actions (Frolova et al. 2020; Slapak et al. 2020; Künnapuu et al. 2021). In addition, the new applications of these interesting compounds/biomolecules and their limitations have been discussed and described (Wang et al. 2020; Bartošová-Sojková et al. 2021).
dc.languageEnglish
dc.subject.classificationbic Book Industry Communication::G Reference, information & interdisciplinary subjects::GP Research & information: general
dc.subject.otherMMP
dc.subject.otherMMP2
dc.subject.otherMMP9
dc.subject.otherMMP7
dc.subject.otherMMP14
dc.subject.othermatrix metalloproteases
dc.subject.otherPDAC
dc.subject.otherpancreatic cancer
dc.subject.otherBowman–Birk inhibitor
dc.subject.otherranacyclin
dc.subject.othertrypsin inhibitor
dc.subject.otherstructure–activity relationship
dc.subject.othersynergistic effect
dc.subject.otherGentamicin
dc.subject.othermatrix metalloproteinase
dc.subject.otherextracellular matrix
dc.subject.othernuclei
dc.subject.othercancer
dc.subject.otherapoptosis
dc.subject.otherimmune response
dc.subject.othercysteine protease inhibitor
dc.subject.otherstefin
dc.subject.othersignal peptide
dc.subject.otherparasite
dc.subject.otherphylogenetic analysis
dc.subject.otherdiversification
dc.subject.otherprotein structure
dc.subject.othervascular endothelial growth factors (VEGFs)
dc.subject.otherVEGF-A
dc.subject.otherPlGF
dc.subject.otherVEGF-B
dc.subject.otherVEGF-C
dc.subject.otherVEGF-D
dc.subject.otherangiogenesis
dc.subject.otherlymphangiogenesis
dc.subject.otherCCBE1
dc.subject.otherproteases
dc.subject.otherADAMTS3
dc.subject.otherplasmin
dc.subject.othercathepsin D
dc.subject.otherKLK3
dc.subject.otherprostate-specific antigen (PSA)
dc.subject.otherthrombin
dc.subject.otherwound healing
dc.subject.othermetastasis
dc.subject.otherproteolytic activation
dc.subject.othervascular biology
dc.subject.otherlymphedema
dc.titleProteases—From Basic Structure to Function to Drug Design as Targeted Therapy
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-2574-7
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036525754
oapen.relation.isbn9783036525747
oapen.pages93
oapen.place.publicationBasel, Switzerland


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/